Bistriazenes as chemotherapeutic agents
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsChristopher J. Michejda, Jeffrey J. Blumenstein
Life of this patent
Estimating the term…
Abstract
The present invention is directed to bistriazene compounds, pharmaceutical compositions containing effective anti-cancer amounts of these compounds, a method for treating cancer comprising administering to affected subjects an anti-cancer effective amount of a bistriazene compound, and the use of bistriazene compounds as crosslinking reagents applicable to the synthesis and manipulation of polymeric macromolecules.
Claims4
A pharmaceutical composition, comprising an anti-cancer effective amount of a compound of the formula:
- ##STR5## wherein the Linker is selected from the group consisting of alkylene, substituted alkylene of chain length 1-20, aralkylene or substituted aralkylene wherein the triazene moieties are bonded to said Linker either directly, or via the alkyl groups of said Linker when such alkyl groups are present, polycyclic aralkylene, heterocyclic aralkylene, and their substituted derivatives wherein the triazene moieties are separated by 1-30 carbon atoms;
- EG.sub.1 and EG.sub.2 are the same or different, and each is a member selected from the group consisting of alkyl, substituted alkyl of chain length 1-20, aralkyl or substituted aralkyl, polycyclic aralkyl, aryl groups and heterocyclic groups of 2-40 non-hydrogen atoms, containing 1-6 rings;
- and
- R and R' are the same or different, and each is a member selected from the group consisting of the members defined above for EG.sub.1, EG.sub.2 and hydrogen;
- or a physiologically acceptable salt thereof and a non-aqueous pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising an anti-cancer effective amount of a substantially pure bistriazene compound selected from the group consisting of 1,2-Bis(methyltriazeno)ethane, 1,4-Bis(methyltriazeno)butane, 1,4-Bis(methyltriazeno)-trans-2-butene, .alpha.,.alpha.'-Bis(methyltriazeno)-p-xylene, trans-1,4-Bis(1,3-dimethyltriazeno)cyclohexane, .alpha.,.alpha.'-Bis(methyltriazeno)-o-xylene, and a physiologically acceptable salt thereof, and a non-aqueous pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising an anti-cancer effective amount of a substantially pure bistriazene compound selected from the group consisting of 1,2-Bis(methyltriazeno)ethane, 1,4-Bis(methyltriazeno)butane, 1,4-Bis(methyltriazeno)-trans-2-butene, .alpha.,.alpha.'-Bis(methyltriazeno)-p-xylene, trans-1,4-Bis(1,3-dimethyltriazeno)cyclohexane, .alpha.,.alpha.'-Bis(methyltriazeno)-o-xylene, and a physiologically acceptable salt thereof, and an anti-cancer effective amount of a compound selected from the group consisting of bis(2-chloroethyl)nitrosourea, mitomycin, cyclophosphamide, ifosphamide, and any other conventional chemotherapeutic alkylating agent.
Dependencies are inferred from the claim text.